In a large analysis of prostate cancer patients treated internationally across 12 randomized trials, research from UCLA Jonsson Comprehensive Cancer Center suggests that it is almost universally optimal for men to receive androgen deprivation therapy during and after radiation therapy, rather than before and during RT.
A urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published April 18 in JAMA Oncology.
